Overview of DHIVY
DHIVY is a significant addition to the treatment arsenal for Parkinson's Disease (PD), particularly notable for being the first and only carbidopa/levodopa (CD/LD) fractional tablet designed to be divided. This innovation was brought to market by Avion Pharmaceuticals, LLC, a division of Alora Pharmaceuticals, following FDA approval in November 2021[3][5].
Market Positioning
Market Size and Growth
The global Parkinson's Disease Drugs Market, within which DHIVY operates, is estimated to be valued at USD 5.56 billion in 2024 and is projected to reach USD 6.63 billion by 2029, growing at a CAGR of 3.58% during the forecast period (2024-2029)[1][5].
Regional Dominance
North America, particularly the United States, is expected to dominate the Parkinson's disease drugs market, driven by high healthcare expenditure, the strong presence of major market players, frequent product approvals, and an increasing number of PD cases[1][3][5].
Product Approval and Launch
DHIVY received FDA approval in November 2021 and was commercially released in February 2022. This approval is significant as it addresses the need for more flexible and manageable treatment options for patients with PD, who often require precise dosing adjustments[1][3][5].
Pricing and Affordability
The cost for DHIVY (25 mg-100 mg) oral tablets is approximately $352 for a supply of 100 tablets, depending on the pharmacy. This pricing is for cash-paying customers and does not include insurance plans. A generic version of carbidopa/levodopa is also available, priced significantly lower, around $14.27 for 30 tablets[2].
Cost Implications
While DHIVY offers a unique dosing flexibility, its cost is relatively high compared to generic alternatives. However, the convenience and precision it offers may justify the higher cost for some patients. The high cost associated with research and development, as well as the production of innovative drugs like DHIVY, is a common challenge in the PD drugs market[1][2].
Market Drivers and Restraints
Drivers
- Increasing Prevalence of Parkinson's Disease: The rising number of PD cases, driven by an aging population and changing lifestyle patterns, is a key driver for the market growth[4][5].
- Strategic Partnerships and Innovations: Major players like UCB and AbbVie are taking strategic steps, such as commercialization agreements and new drug applications, which enhance market growth[1][3][5].
- Frequent Product Approvals: FDA approvals for new and innovative treatments, like DHIVY, contribute significantly to market growth[1][3][5].
Restraints
- High Costs and R&D Expenditure: The high costs associated with the research and development of drugs like DHIVY can hinder market growth. These costs are often passed on to consumers, making the treatments less accessible[1][5].
- Adverse Events and Safety Concerns: Side effects and long-term safety concerns associated with PD treatments can reduce patient compliance and healthcare provider confidence in prescribing these drugs[4].
Competitive Landscape
The Parkinson's disease drugs market is highly competitive, with several major players actively involved in research, development, and commercialization of new treatments. Companies like UCB, Novartis, AbbVie, and Avion Pharmaceuticals are continuously innovating and expanding their product portfolios[1][3][5].
Technological Advancements and Future Opportunities
Drug Delivery Systems
Technological advancements in drug delivery systems are expected to drive excellent opportunities for the PD drugs market. Innovations like fractional tablets, as seen with DHIVY, enhance treatment efficacy and patient compliance[4].
Personalized Medicine
The focus on personalized medicine is another trend influencing the market. Tailored treatment approaches can improve patient outcomes and drive market growth[4].
Key Takeaways
- Market Growth: The PD drugs market, including DHIVY, is expected to grow at a CAGR of 3.58% from 2024 to 2029.
- Regional Dominance: North America, particularly the United States, will dominate the market due to high healthcare expenditure and frequent product approvals.
- Pricing: DHIVY is priced around $352 for 100 tablets, with generic alternatives available at lower costs.
- Drivers and Restraints: Increasing PD prevalence, strategic partnerships, and frequent product approvals drive the market, while high costs and safety concerns restrain it.
- Competitive Landscape: The market is highly competitive with major players innovating and expanding their product portfolios.
FAQs
What is DHIVY and how is it used?
DHIVY is the first and only carbidopa/levodopa (CD/LD) fractional tablet designed to be divided, used for treating Parkinson's Disease. It was approved by the FDA in November 2021 and commercially released in February 2022[3].
How much does DHIVY cost?
The cost for DHIVY (25 mg-100 mg) oral tablets is approximately $352 for a supply of 100 tablets, depending on the pharmacy[2].
What are the key drivers for the Parkinson's disease drugs market?
Key drivers include the increasing prevalence of Parkinson's Disease, strategic partnerships among major players, and frequent product approvals by regulatory bodies like the FDA[1][4][5].
What are the main restraints for the Parkinson's disease drugs market?
High costs associated with research and development, as well as adverse events and safety concerns related to the treatments, are significant restraints[1][4][5].
Which region is expected to dominate the Parkinson's disease drugs market?
North America, particularly the United States, is expected to dominate the market due to high healthcare expenditure, strong presence of major market players, and frequent product approvals[1][3][5].
Sources
- Research and Markets: Parkinson's Disease Drugs - Market Share Analysis, Industry Trends ...
- Drugs.com: Dhivy Prices, Coupons, Copay Cards & Patient Assistance
- Mordor Intelligence: Global Parkinson's Disease Drugs Market Trends
- Allied Market Research: Levodopa Market Size, Growth Analysis | Forecast - 2032
- Mordor Intelligence: Global Parkinson's Disease Drugs Market Size - Mordor Intelligence
